Discontinuation of Renin–Angiotensin System Inhibitors and Risk of End‐Stage Renal Disease and Cardiovascular Outcomes Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Taiwanese Cohort Study
Our results support continuing RASi treatment even when the eGFR declines to below 45 mL/min/1.73 m<sup>2</sup> based on potential renal, cardiovascular, and survival benefits.
Authors
- Yaa‐Hui Dong (ORCID: https://orcid.org/0000-0001-5336-4113)
- Li‐Chiu Wu
- Sengwee Toh
- Chia‐Hsuin Chang
Institutions
- Harvard University (US)
- National Yang Ming Chiao Tung University (TW)
- National Taiwan University (TW)
- Harvard Pilgrim Health Care (US)
- National Taiwan University Hospital (TW)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1002/pds.70323
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00